Results 41 to 50 of about 60,513 (321)

Advances in myelofibrosis: a clinical case approach

Haematologica, 2013
Primary myelofibrosis is a member of the myeloproliferative neoplasms, a diverse group of bone marrow malignancies. Symptoms of myelofibrosis, particularly those associated with splenomegaly (abdominal distention and pain, early satiety, dyspnea, and ...
John O. Mascarenhas, Attilio Orazi, Kapil N. Bhalla, Richard E. Champlin, Claire Harrison, Ronald Hoffman   +5 more
doaj   +1 more source

Comparison of different criteria for the diagnosis of primary myelofibrosis reveals limited clinical utility for measurement of serum lactate dehydrogenase

Haematologica, 2010
Primary myelofibrosis shows histological and pathogenetic overlap with essential thrombocythemia and polycythemia vera. Several diagnostic classifications have been proposed for primary myelofibrosis, although little is known about their clinical utility.
Philip A. Beer, Peter J. Campbell, Anthony R. Green   +2 more
doaj   +1 more source

Tetraspanin CD9 participates in dysmegakaryopoiesis and stromal interactions in primary myelofibrosis

Haematologica, 2015
Primary myelofibrosis is characterized by clonal myeloproliferation, dysmegakaryopoiesis, extramedullary hematopoiesis associated with myelofibrosis and altered stroma in the bone marrow and spleen.
Christophe Desterke, Christophe Martinaud, Bernadette Guerton, Lisa Pieri, Costanza Bogani, Denis Clay, Frederic Torossian, Jean-Jacques Lataillade, Hans C. Hasselbach, Heinz Gisslinger, Jean-Loup Demory, Brigitte Dupriez, Claude Boucheix, Eric Rubinstein, Sophie Amsellem, Alessandro M. Vannucchi, Marie-Caroline Le Bousse-Kerdilès   +16 more
doaj   +1 more source

Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT

Leukemia, 2021
JAK1/2 inhibitor ruxolitinib (RUX) is approved in patients with myelofibrosis but the impact of pretreatment with RUX on outcome after allogeneic hematopoietic stem cell transplantation (HSCT) remains to be determined.
N. Kröger, Giulia Sbianchi, Tiarlan Sirait, C. Wolschke, D. Beelen, J. Passweg, M. Robin, R. Vrhovac, G. Helbig, K. Sockel, E. Conneally, M. Rubio, Y. Beguin, J. Finke, P. Bernasconi, E. Morozova, J. Clausen, P. A. von dem Borne, N. Schaap, W. Schroyens, F. Patriarca, N. Di Renzo, Z. Yeğin, P. Hayden, D. Mclornan, I. Yakoub-Agha   +25 more
semanticscholar   +1 more source

Splanchnic vein thrombosis in myeloproliferative neoplasms: Pathophysiology and molecular mechanisms of disease [PDF]

, 2016
Myeloproliferative neoplasms (MPNs) are the most common underlying prothrombotic disorder found in patients with splanchnic vein thrombosis (SVT). Clinical risk factors for MPN-associated SVTs include younger age, female sex, concomitant hypercoagulable ...
How, Joan, Oh, Stephen T, Zhou, Amy
core   +2 more sources

Transcriptional profiling of whole blood identifies a unique 5-gene signature for myelofibrosis and imminent myelofibrosis transformation. [PDF]

PLoS ONE, 2014
Identifying a distinct gene signature for myelofibrosis may yield novel information of the genes, which are responsible for progression of essential thrombocythemia and polycythemia vera towards myelofibrosis.
Hans Carl Hasselbalch, Vibe Skov, Thomas Stauffer Larsen, Mads Thomassen, Caroline Hasselbalch Riley, Morten K Jensen, Ole Weis Bjerrum, Torben A Kruse   +7 more
doaj   +1 more source

Ruxolitinib for myelofibrosis

Experimental and Therapeutic Medicine, 2013
The aim of the present study was to assess the beneficial and harmful effects of ruxolitinib in patients with myelofibrosis (MF). The Cochrane databases, PubMed and Embase were searched for studies published up to October 2012. Randomised controlled trials assessing ruxolitinib versus a placebo or the best available therapy in patients with MF were ...
Jinjing Tan, Qing Chen, Guangliang Wu, Li Su, Yan Yan, Nong Tang, Juanjuan Xie, Lian Gu, Baoyun Liang   +8 more
openaire   +4 more sources

Platelets as mediators of Thromboinflammation in chronic Myeloproliferative Neoplasms [PDF]

, 2019
Chronic myeloproliferative neoplasms (MPN) are stem cell disorders driven by mutations in JAK2, CALR, or MPL genes and characterized by myeloid proliferation and increased blood cell counts.
Heller, Paula Graciela, Marin Oyarzún, Cecilia Paola   +1 more
core   +1 more source

Updated results of the placebo‐controlled, phase III JAKARTA trial of fedratinib in patients with intermediate‐2 or high‐risk myelofibrosis

British Journal of Haematology, 2021
Fedratinib, an oral Janus kinase‐2 (JAK2) inhibitor, reduces splenomegaly and improves symptom burden in patients with myelofibrosis. Regulatory approval of fedratinib 400‐mg daily was based on results of an updated analysis of the pivotal phase III ...
A. Pardanani, A. Tefferi, T. Masszi, E. Mishchenko, M. Drummond, E. Jourdan, A. Vannucchi, M. Jurgutis, V. Ribrag, A. Rambaldi, L. Koh, S. Rose, Jun Zhang, C. Harrison   +13 more
semanticscholar   +1 more source

Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis

Leukemia, 2020
Myeloproliferative neoplasm (MPN)-associated myelofibrosis (MF) is characterized by cytopenias, marrow fibrosis, constitutional symptoms, extramedullary hematopoiesis, splenomegaly, and shortened survival.
M. Talpaz, J. Kiladjian
semanticscholar   +1 more source